Drugs / HS235
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07143448 | Oct 2025 → Apr 2027 expected | pulmonary arterial hypertension | 35Pharma Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07123779 | Sep 2025 → Sep 2027 expected | diastolic heart failure, pulmonary hypertension | 35Pharma Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06714825 | Nov 2024 → Dec 2025 | — | 35Pharma Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-12-09 | 35Pharma Inc | Results 35Pharma Announces Initial HS235 Phase 1 Healthy Volunteer Biomarker Results During Oral Presentation at the 22nd Global Cardiovascular Clinical Trialist Forum. 35pharma.com ↗
Phase 1 SAD data indicate HS235 was generally well tolerated, achieved sustained target engagement, and improved body composition and circulating markers of cardiometabolic disease in healthy volunteers |
| 2025-11-09 | 35Pharma Inc | Results 35Pharma Presents HS235 Pre-Clinical Heart Failure and Pulmonary Hypertension Data in Moderated Poster Session at AHA 2025. 35pharma.com ↗
35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today presented pre-clinical HS235 data in an oral moderated poster presentation at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, LA. |
| 2025-11-04 | 35Pharma Inc | Results 35Pharma Oral Presentation at ObesityWeek 2025: HS235 Demonstrates Activity in Pre-Clinical Models of Obesity and Heart Failure. 35pharma.com ↗
During the oral presentation, Maureen O’Connor, Ph.D., Chief Scientific Officer of 35Pharma, presented pre-clinical data demonstrating that HS235 effectively addresses major hallmarks of HFpEF by: |
| 2025-09-28 | 35Pharma Inc | Results 35Pharma Announces Oral Presentation of HS235 Pre-Clinical Data in Models of Pulmonary Hypertension at ERS 2025. 35pharma.com ↗
During an oral presentation at ERS 2025, 35Pharma Chief Scientific Officer Maureen O’Connor shared pre-clinical data with HS235 supporting its pulmonary and cardiac activity in murine models of pulmonary hypertension and heart failure. |
| 2024-11-03 | 35Pharma Inc | Results 35Pharma Announces Oral Presentation of HS235 Pre-Clinical Data in Obese HFpEF at Obesity Week 2024. 35pharma.com ↗
HS235 improved body composition, and rescued left ventricular function and exercise capacity in a murine obese HFpEF model |
| 2024-10-18 | 35Pharma Inc | Regulatory 35Pharma Cleared to Initiate Clinical Development of HS235, Novel Activin and GDF Inhibitor for Cardiometabolic Disease and Obesity. 35pharma.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS235 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07143448 ↗ |
| Action | Inhibit | “Activin Signaling Inhibitor HS235” NCT07143448 ↗ |
| Route | Subcutaneous | “HS235 Subcutaneous Injection” NCT06714825 ↗ |